Voyageur Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug '25 Aug 31, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020
Selling, General & Admin	3.11	1.7	1.34	1.75	2.05	1
Depreciation & Amortization Expenses	0	0	0	0	0	0
Research & Development	0.25	-	-	-	-	-
Other Operating Expenses	-	0.01	0.05	0.01	-	-
Total Operating Expenses	3.36	1.71	1.4	1.76	2.05	1
Operating Income	-3.36	-1.71	-1.4	-1.76	-2.05	-1
Interest Income	-	-	-	-	-	0.01
Other Non-Operating Income (Expense)	-	-	-	-0	-	-0.15
Total Non-Operating Income (Expense)	-	-	-	-0	-	-0.14
Pretax Income	-3.36	-1.71	-1.4	-1.76	-2.05	-1.14
Net Income	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14
Net Income to Common	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14
Shares Outstanding (Basic)	156	138	131	108	95	71
Shares Outstanding (Diluted)	156	138	131	108	95	71
Shares Change (YoY)	14.67%	5.46%	21.03%	13.89%	34.24%	22.58%
EPS (Basic)	-0.03	-0.01	-0.01	-0.02	-0.02	-0.02
EPS (Diluted)	-0.03	-0.01	-0.01	-0.02	-0.02	-0.02
Free Cash Flow	-2.44	-0.3	-0.99	-1.72	-1.67	-0.27
Free Cash Flow Per Share	-0.02	-0.00	-0.01	-0.02	-0.02	-0.00
EBITDA	-3.36	-1.71	-1.4	-1.75	-2.04	-1
EBIT	-3.36	-1.71	-1.4	-1.76	-2.05	-1

Updated Aug 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.